Negative
●
Proactive Investors
●
4 months ago
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of the year delivered a statistical miss that has prompted a wave of analyst downgrades. The company disclosed on Friday that its phase 3 trial of fianlimab, combined with its approved immunotherapy cemiplimab, as a first-line treatment for advanced m...